This story is based on an ASTCT press release.
The American Society for Transplantation and Cellular Therapy, or ASTCT, announced Dr. Brenda M. Sandmaier as the ASTCT president in 2022-2023.
Sandmaier is a professor in the Clinical Research Division at Fred Hutchinson Cancer Research Center and professor of Medicine in the Division of Medical Oncology at the University of Washington School of Medicine. She is a member of ASTCT and the American Society of Hematology, or ASH.
“The opportunity to serve as president of ASTCT is an honor,” Sandmaier said. “My career has been focused on providing allogeneic [donor bone marrow or blood stem cell] transplantation immunotherapy to more patients with hematologic malignancies [blood cancers] around the world, which is in line with the mission of ASTCT. With the ASTCT board of directors, I look forward to advancing science and education in this important and ever-evolving field of medicine.”
Sandmaier becomes president of ASTCT after sequential terms as vice president and president-elect. Following her one-year term as president, she will serve as the society’s immediate past president.
Sandmaier’s research focuses on extending the benefits of transplant immunotherapy to a broader range of patients, including blood stem cell transplant patients who are older or have medical comorbidities, and those who do not have fully HLA-matched (or tissue type-matched) donors. Translating from her laboratory’s preclinical studies, she has conducted clinical trials to prevent graft-vs.-host disease after transplantation with different donor types. Graft-vs.-host disease is a common complication of blood stem cell transplant in which immune cells from the donor attack the patient’s healthy tissues. Sandmaier’s lab has also developed less-toxic conditioning (pre-transplant preparatory) regimens, such as radioimmunotherapy, that have been clinically translated to treat patients with hematologic malignancies and nonmalignant, including inherited, blood disorders.
Sandmaier previously served on several national committees for ASTCT, ASH and the Center for International Blood and Marrow Transplant Research, or CIBMTR, including serving as director at large on the ASTCT board of directors, member and chair of the ASH Scientific Committee on Transplantation Biology, member and chair of the CIBMTR Nominating Committee and, most recently, chair of the CIBMTR Acute Leukemia Working Committee.
Sandmaier assumed the role of ASTCT president at the 2022 joint annual meeting of the ASTCT and CIBMTR, called the Transplantation & Cellular Therapy, or Tandem, Meetings, which took place from April 23-26 in Salt Lake City.
In addition to Fred Hutch science presented at the meeting, several Fred Hutch researchers were honored there for their contributions to the field of transplantation and cellular therapy:
On April 1, 2022, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance became Fred Hutchinson Cancer Center, a single, independent, nonprofit organization that is also a clinically integrated part of UW Medicine and UW Medicine’s cancer program. Read more about the restructure.
Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at email@example.com
Every dollar counts. Please support lifesaving research today.